‘Global Pain Relieving Drugs Market Worth $67.8bn In 2016’ Says Visiongain Report

29 August 2016
Pharma

Visiongain’s new report Pain Relieving Drugs Market Forecast 2017-2027: Neuropathic Pain Relieving Drugs, Narcotic Pain Relieving Drugs, Non-Narcotic Pain Relieving Drugs, Anti-Arthritic Pain Relieving Drugs, Anti-Migraine Pain Relieving Drugs indicates that the global pain relieving drugs market is worth $67.8bn in 2016.

The global pain relieving drugs market is expected to grow at a CAGR of 2.1% from 2021-2027. The market is expected to grow from $67.8bn in 2016 to $75.2bn in 2027.

The lead analyst of the report said: “The pain relieving drug market has become a mainstay of the modern pharmaceutical industry providing people relief from pain caused by numerous diseases and conditions. Advances in modern technologies have help to provide the pain relieving drug market much room for significant revenue growth in the near future as innovation new drug candidates are developed. Though numerous blockbusters, pain relieving medications will face increased competition from generic erosion in the coming decade.”

The 308 page report contains 122 tables and 121 charts that add visual analysis in order to explain the developing trends within the Global Pain Relieving Drugs Market. Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: Neuropathic Pain Relieving Drugs, Narcotic Pain Relieving Drugs, Non-Narcotic Pain Relieving Drugs, Anti-Arthritic Pain Relieving Drugs, Anti-Migraine Pain Relieving Drugs and Others.

Visiongain also provides revenue forecasts for the period 2017-2027 for the leading drugs under each leading segment.

The 308 page report offers market forecasts and analysis for 12 leading national markets: US, Japan, Germany, France, UK, Spain, Italy, Russia, Brazil, India, China and the Rest of the World.

This report also discusses the potential pain relieving drugs that are currently being developed in various clinical trial phases.

The Pain Relieving Drugs Market Forecast 2017-2027: Neuropathic Pain Relieving Drugs, Narcotic Pain Relieving Drugs, Non-Narcotic Pain Relieving Drugs, Anti-Arthritic Pain Relieving Drugs, Anti-Migraine Pain Relieving Drugs report will be of value to anyone who wants to better understand the pain relieving drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the pain relieving drugs industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever